SCHEDULE 13G: Madison Avenue Entities Disclose 6.8% Passive Stake in CARGO Therapeutics

A group of investment entities led by Madison Avenue Partners LP and Eli Samaha have disclosed a passive 6.8% beneficial ownership stake in CARGO Therapeutics, Inc. common stock.

Summary

• Madison Avenue Partners LP, Madison Avenue International LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC, and Eli Samaha (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 3,113,693 shares of CARGO Therapeutics, Inc. common stock.
• This represents approximately 6.8% of the outstanding common stock of CARGO Therapeutics, Inc.
• The percentage is based on 46,052,368 common shares outstanding as of March 5, 2025, as disclosed in the Issuer's Form 10-K.
• The acquisition of shares was not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a new significant passive stake by an institutional investor group is generally viewed as a positive signal, indicating investor confidence in the company, although it does not provide operational or financial performance updates.

Positives

• A significant institutional investor group has taken a substantial passive stake (6.8%) in CARGO Therapeutics, which can be interpreted as a vote of confidence in the company's long-term prospects.

Negatives

• No negative information is disclosed in this Schedule 13G filing.

Risks

• No specific risks related to CARGO Therapeutics, Inc. operations or financial health are mentioned in this ownership disclosure.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance regarding CARGO Therapeutics, Inc.'s future operations or financial performance.

Management Comments

• The filing includes a certification by Eli Samaha on behalf of the Reporting Persons stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

The disclosure of a significant passive stake by an institutional investor group in a biotechnology company like CARGO Therapeutics, Inc. suggests potential investor confidence in the sector or the company's specific therapeutic pipeline, aligning with broader trends of institutional capital allocation into promising life sciences ventures.

Comparison to Industry Standards

• This Schedule 13G filing is a standard regulatory disclosure for investors acquiring a significant passive stake (over 5%) in a public company.
• It does not provide specific operational or financial results for comparison to industry benchmarks or competitors.
• The filing's content is limited to ownership details and the passive nature of the investment, which is consistent with typical Schedule 13G filings across all industries.

Stakeholder Impact

• Shareholders may view the entry of a new significant institutional investor as a positive indicator of market confidence, potentially leading to increased investor interest.
• The filing itself does not directly impact employees, customers, suppliers, or creditors, as it pertains solely to ownership structure.

Next Steps

• The Reporting Persons will continue to hold their investment in CARGO Therapeutics, Inc. as a passive stake, and any future changes in their beneficial ownership exceeding certain thresholds would necessitate further SEC filings.

Key Dates

Recommendation

Keywords

CARGO Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Madison Avenue Partners, Eli Samaha, Common Stock, Biotechnology, Healthcare Investment